The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

People with multiple sclerosis (MS) face a significantly higher ... and often progresses to physical and cognitive disability. MS takes several forms, with new symptoms occurring either in ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Experimental drug shows promise for advanced MS, delaying disability. Learn how Black Americans may benefit & why clinical ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...